|
Characteristics
|
Factors(Frequency)
|
%
|
|---|
|
Age (years) Range
|
< 30 years (27)
|
27.0
|
|
30–40 years (43)
|
43.0
|
|
> 40 years (30 )
|
30.0
|
|
Sex
|
Female (53)
|
53.0
|
|
Male (47)
|
47.0
|
|
BMI (kg/m2)
|
Low (47)
|
47.0
|
|
Normal (31)
|
31.0
|
|
Overweight (7)
|
7.0
|
|
Obese (15)
|
15.0
|
|
Level of education
|
None (5)
|
5.0
|
|
Primary (51)
|
51.0
|
|
Secondary (38)
|
38.0
|
|
Tertiary (6)
|
6.0
|
|
Monthly Income
|
< 50,000frs (77)
|
77.0
|
|
> 50,000frs (23)
|
23.0
|
|
Alcohol intake
|
Yes (56)
|
56.0
|
|
No (44)
|
44.0
|
|
Cigarette or Tobacco intake
|
No (73)
|
73.0
|
|
Yes (27)
|
27.0
|
|
Year of diagnosis
|
< 1 Year (84)
|
84.0
|
|
1–3 Years (4)
|
4.0
|
|
> 3 Years (12)
|
12.0
|
|
CD4 class (cells/ mm3)
|
< 200 (57)
|
57.0
|
|
> 200 (43)
|
43.0
|
|
WHO stages
|
stage 1 (14)
|
14.0
|
|
stage2 (45)
|
45.0
|
|
stage 3 (37)
|
37.0
|
|
stage 4 (4)
|
4.0
|
|
Drug type
|
TDF + 3TC + EFV(64)
|
64.0
|
|
AZT + 3TC + EFV (22)
|
22.0
|
|
AZT + 3TC + NVP (14)
|
14.0
|
- 3TC: Lamivudine, AZT: Zidovudine, BMI: Body mass index, EFV: Efavirenz, NVP: Nevirapine; TDF: Tenofovir
